Answers are grounded in this paper and cite their sources.
Ret-papillary thyroid carcinoma (PTC) chimeras are rearranged forms of ret found in papillary thyroid carcinoma (PTC), which include three main isoforms, even if additional variations have also been reported (1). Ret-PTC1 and ret-PTC3 arise from chromosome 10 inversions, (fused genes: H4 and RFG/ELE, respectively), whereas the rarer ret/PTC2 arises from a chromosome 10/17 translocation. The rearrangements result in constitutive activation of ret, which is phosphorylated on tyrosine and translocated from the membrane to the cytoplasm. The recent paper by Learoyd et al. (2), specifically analyzed the clinical outcome in patients with PTC on the basis of the presence or absence of ret/PTC expression. Unfortunately, in their series of 50 adult patients with PTC, only 4 had ret/PTC activation, as ret/PTC1 in all cases. They concluded that, in their series, “there was no significant difference between the 2 clinical patient groups (MACIS score <7 vs. >7) with respect to the presence or absence of ret/PTC in the patient’s tumor.” It has been suggested that the presence of ret/PTC may be associated with a greater likelihood of metastatic spread and poorer prognosis (3–5). The prevalence of ret/PTC rearrangements in PTC series from around the world varies widely from approximately 3–85% and is influenced by several factors, including methods of detection. In particular, studies from the Chernobyl area reported a ret/PTC prevalence on the order of 70%. Most of the children in the studies had lymphonodal involvement (6, 7), and some required early re-operation for local recurrence, suggesting an aggressive behavior on the part of the tumor. Interestingly, in these case the ret/PTC3 isoform was more prevalent than ret/PTC1 (6).
No takes yet. Share an insight, caveat, or question.
Cetta et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: